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Abstract 
Nowadays medical software is a continuously growing market. It is essential 
for the manufacturers of this type of medical product to follow mandatory 
regulatory requirements and implement the necessary measures in the company 
in order to market their product in different countries. 
The medical product to be certified is OneCare Sensing marketed by ISA, a 
monitoring software solution intended to collect, store, display, transmit and 
provide alerts of physiological parameters such as temperature, blood glucose 
and pressure and pulse oximetry of users at home allowing distance monitoring 
by family or clinicians, reducing journeys to healthcare facilities or domiciliary 
medical visits. 
The aim of this thesis is to collect and analyze the regulatory requirements 
of this medical software in Europe, Brazil and USA. Regarding Europe a more 
pratical work was made by implementing in the company all the necessary 
requirements in order to obtain CE marking following the Medical Devices 
Directive 93/42/EEC. In the USA it is necessary FDA clearance by filling a 
510(k) submission and implement a quality management system according to 
FDA QSR – 21CFR Part 820. Concerning Brazil, the regulatory agency is 
ANVISA and the submission type for this device is a registro. Also a quality 
management system according to the GBMP must be implemented within the 
company.  
It was found that these regions despite having independent regulatory 
requirements they share some similarities. This study allowed the product to be 
one step closer to be marketed in Europe, Brazil and USA.  
 
 
 
Keywords: medical software, medical device, certification process, CE 
marking, directive 93/42/EEC, FDA clearance, registro ANVISA, regulatory 
requirements in Europe, USA and Brazil. 
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Resumo 
Actualmente o software médico é um mercado em crescimento contínuo. É 
essencial para um fabricante deste tipo de produto médico seguir os requisitos 
regulamentares obrigatórios e implementar as medidas necessárias na empresa 
para poder comercializar o seu produto em países diferentes. 
O produto médico a ser certificado é o OneCare Sensing comercializado pela 
ISA-Intellicare, uma solução de software de monitorização destinado a recolher, 
armazenar, visualizar, transmitir e fornecer alertas de parâmetros fisiológicos 
como temperatura, níveis de glucose e pressão sanguínea e oximetria de pulso 
dos utilizadores em sua casa permitindo a monitorização à distancia de 
familiares ou clínicos, reduzindo as suas deslocações a estabelecimentos de saúde 
ou visitas médicas familiares. 
O objectivo desta tese é recolher e analisar os requesitos regulamentares 
deste software médico na Europa, Brazil e EUA. Relativamente à Europa foi 
realizado um trabalho mais prático implementando na empresa todos os 
requisitos necessários para obter marcação CE seguindo a Directiva Médica 
93/42/EEC. Nos EUA é necessária a autorização da FDA preenchendo uma 
submissão 510(k) e implementando um sistema de gestão de qualidade de 
acordo com FDA QSR – 21CFR Parte 820. Relativamente ao Brasil, a agência 
reguladora é a ANVISA e o tipo de submissão para este dispositivo é o registro. 
Tambem é necessário implementar um sistema de gestão de qualidade de acordo 
com GBMP na empresa. 
Foi descoberto que estas regiões apesar de possuirem requisitos regulatórios 
independentes possuem algumas semelhanças entre si. Este estudo permite que o 
produto em questão fique um passo mais próximo de ser comercializado na 
Europa, Brazil e EUA.  
 
Palavras-chave: software médico, dispositivo médico, processo de certificação, 
marcação CE, directiva 93/42/EEC, autorização da FDA, registro ANVISA, 
requisitos regulamentares na Europa, EUA e Brasil. 
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1 Introduction 
1.1 Framework 
Nowadays the demand of more and better regulatory frameworks ensure that 
the medical products entering the market are safe and effective. The two main 
challenges for companies of these type of products are research and development 
along with keeping up with the updates on regulatory requirements and 
implement them in the company [1].  
Manufacturers of medical devices need to adjust their regulatory framework 
for the countries where their products are sold. If they fail to do this a lot of 
capital could be lost by delaying the marketing of their devices. These 
regulatory requirements include things such as laws, standards, quality systems 
and product classification and registration [2]. 
In Europe, USA and Brazil there are some similarities in the regulatory 
process for medical devices. All systems have a definition of medical device and 
a risk based classification. This classification is a very important step since it 
dictates how to apply the correct regulations and quality systems [2]. 
In Europe the quality system is presented in the Medical Devices Directive 
and applied following the standards such as ISO 13485:2003, in the USA it is 
dictated by the FDA QSR 21 CFR Part 820 and in Brazil the Brazilian Good 
Manufacturing Practices. Despite their differences they share a lot of 
characteristics and usually if you already have one of these quality systems 
implemented it is fairly easy to comply with another one. Other specific 
requirements for each country will be addressed further in this document. 
1.2 Objectives 
The main objective of this project is to prepare the company regarding all 
regulatory requirements to posteriorly obtain CE marking on the product. 
In order to achive this, a study of the OneCare Sensing was made. After, the 
medical device directive 93/42/EEC as carefully analyzed. In the course of this 
analyzis several norms where selected and ISO 13485:2003 was analyzed and 
ISO 14971:2007 implemented in the organization. 
During the course of the work it was also verified that it would be important 
to identify the regulatory requirements for Brazil and USA in order to market 
the product in those regions in the future. This was a very general and 
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theoretical work but nevertheless essential to understand what to be done to 
comply with the legal requirements. 
1.3 Thesis organization 
This thesis is divided in 9 chapters. 
In this chapter the theme, objectives and organization of the document are 
presented in order to provide an introductory framework of the project for the 
reader. 
Chapter 2 is about project management. The company ISA-Intellicare is 
presented, the project contribution and the initial and final scheduling of the 
work are given. 
Chapter 3 describes the medical product being studied. This includes the 
intended use, a small reference of the technology and the physiological signals 
acquired by the product related with pathologies that can be managed and/or 
avoided using OneCare Sensing. 
Chapter 4 provides the state of the art. An introduction and market 
overview is given. Then the players of medical devices, the current EU funded 
program, market products similar to OneCare Sensing and the difficulties and 
barriers in the market are presented. 
Chapter 5 is probably the most important chapter in the document. It 
describes in detail the medical device certification process in Europe and the 
work made during the project. 
Chapter 6 mentions all the relevant normative framework which is applied to 
OneCare Sensing and compares two important standards, ISO 9001:2008 and 
ISO 13485:2003. 
Chapter 7 describes the USA regulatory process for medical devices. In a 
way it tends to be more specific to medical software but doing that in a very 
thorough way was outside the scope of this work. 
Chapter 8 outlines the Brazilian regulatory process for medical devices in a 
similar structure and function of chapter 6. 
Chapter 9 provides the conclusion of this thesis. Future work that needs to 
be done in order to most effectively market the product in these three regions is 
presented. It ends with a brief summary of the project. 
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2 Project management 
2.1 ISA – Intellicare 
ISA-IntelliCare is a provider of products and services in the field of Remote 
Monitoring of Vital Signs and Ambient Assisted Living located at Rua Pedro 
Nunes, Building D, 3030-199, Coimbra, Portugal[3]. 
ISA IntelliCare is a spin-off of ISA. ISA –  Intelligent Sensing Anywhere is a 
technology-based company with an experience of over 20 years in Machine to 
Machine (M2M) ‘ ready-to-go’ , solutions, from software and hardware, 
development to the provision of services. It is a company specialized in two 
business areas –  ISA Energy and ISA Oil & Gas –  that offer and implement 
solutions and innovative services aiming toward efficiency and processes 
improvement in the energy, environment, gas and other fuels areas[4]. 
ISA IntelliCare mission is to offer high value added products and services for 
the global health market, by gathering relevant data about health and well-
being status of the people, real time processing of data, regardless of distance 
and converting it in useful information and knowledge [3]. 
2.2 Project contribution 
This project allowed to find and establish requirements necessary to obtain 
CE marking in a medical software necessary for its marketing in the European 
market. It also provides the legal framework in order to market medical 
software in USA and Brazil. 
Part of the requirements analyzed are compiling a technical file according 
with the MDD which contains all the details about the product and implement 
a quality system specific for medical devices according ISO 13485:2003 –  
Medical devices –  Quality management systems –  Requirements for regulatory 
purposes. 
In this way the project is perfectly aligned with ISA-Intellicare objectives 
and it can also provide help for manufacturers of medical software that need 
information in how to comply with legal requirements in Europe, USA and 
Brazil. 
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2.3 Scheduling the project 
In the first phase of the project, essential tasks identified and planed. This 
was done to comply with the internship objectives in the most effective way but 
during work the schedule was adapted. 
2.3.1 Initial scheduling 
In the initial project proposition the following tasks and planning where 
identified. This is showed below in a Gant diagram. 
Table 1 - Gant diagram: initial scheduling. 
Cronogram 
      Planning M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 Phase description 
Phase I                     
Familiarization with ISA's 
working mode 
Phase II                     
Study the equipment 
OneCare 
Phase III                     
Study the applicability of the 
Directive 93/42/EEC to 
OneCare and compile a 
technical file 
Phase IV                     
Studying ISO 13485:2003 and 
define processes to ensure 
compliance with this 
standard 
Phase V                     
Notified Body communication 
to receive certification 
Phase VI                     
Writing and present Master's 
thesis 
2.3.2 Final scheduling 
In the course of the project it was found that some tasks needed more time 
to be completed. Also it was agreed with the supervisor that Phase V should be 
substituted by “providing legal framework on medical devices marketing in 
Brazil and USA”. Below is presented a Gant diagram on the final Scheduling of 
the project. 
Table 2 - Gant diagram: final scheduling. 
Cronogram 
      Planning M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 Phase description 
Phase I                     
Familiarization with ISA's 
working mode 
Phase II                     
Study the equipment 
OneCare 
Phase III                     
Study the applicability of 
the Directive 93/42/EEC to 
OneCare and compile a 
technical file 
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Cronogram 
      Planning M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 Phase description 
Phase IV                     
Studying ISO 13485:2003 
and define processes to 
ensure compliance with this 
standard 
Phase V                     
Legal framework for 
medical devices in USA and 
Brazil 
Phase VI                     
Writing and present 
Master's thesis 
 
7 
3 Product description 
3.1 Intended use 
This is the first step in order to obtain medical device certification in 
Europe. It’s necessary to define an intended use for the medical device. 
OneCare Sensing is a monitoring software solution intended to collect, store, 
display and transmit physiological measurements of users at home allowing 
distance monitoring by family or clinicians, reducing journeys to healthcare 
facilities or domiciliary medical visits [5]. 
Implemented in a tablet it collects, stores and displays physiological data 
captured in commercially available medical devices. It allows the transmission of 
the data to a remote secure server and storage in a database. Then the data can 
be available for consultation in the web by the user and clinicians for analysis 
and intervention. The medical devices that can be connected to the tablet are a 
glucose meter, weight scale, pulse oximeter, blood pressure monitor and 
thermometer. All of these sensors have CE marking according to the respective 
medical devices directives. One version of the software provides only real-time 
monitoring and the other does the same and emergency monitoring emitting 
alerts. 
3.2 Telemedicine 
Telemedicine or telehealth is defined by the American Telemedicine 
Association [6] as “ the use of medical information exchanged from one site to 
another via electronic communications to improve patients’  health status” . It 
could also be more generally defined as electronic communication technologies 
to provide health care at a distance [7].  Basically it refers to remote care 
monitoring and delivery that occurs outside clinical environment and usually in 
the patients’  residence. 
The percentage of adults over 65 years of age is increasing rapidly and with 
this healthcare costs are escalating beyond the ability of these older adults to 
pay for services [8]. To achieve the goal of improving the quality of elderly care 
it is essential to provide timely information and tools to care providers that 
enable them to proactively support independence and aging in place. This will 
allow reducing stress, lowering costs and unnecessary assistance. Continuous 
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monitoring of individual parameters will allow earlier diagnosis and prevention 
of health problems in the future as well of acute emergency events. 
Recent advances in telehealth offer great opportunities for older people 
enabling them to live independently in their homes receiving care and remote 
health assistance from family and healthcare providers. Important issues as 
patients’  acceptance and accessibility must be addressed since the end users, 
particularly elderly, may not be able on accepting the technology as a tool for 
healing [9]. 
One great advantage of the system is to provide health care for a large group 
of people, where previously they were limited by time and distance from the 
patient. Regarding the technical, economical and clinical aspects of home based 
telemedicine numerous studies demonstrated the effectiveness of this 
technology[10]. 
As aged population is increasing in developed countries it is expected that 
more care and monitoring will be needed. The costs of these services are 
becoming more affordable and portable devices become smaller and more user-
friendly. The design of interconnected devices and sensors must be non-
obtrusiveness and can be comfortably worn. Also they must be reliable and not 
affect the movement of users. 
The future of this technology will pass by making data communication 
faster, safer and more economical and optimization of reliability. The factors 
that could affect reliability are network disruption, the main cause of failure in 
telemedicine systems; link failures in the data transmission, performance of the 
network. Those main causes of failure are in the wireless link or hardware and 
this will be optimized in the future [9]. 
3.3 Signals acquired 
OneCare Sensing is versatile product that can use sensors from different 
brands. In this section the sensors are depicted as an example of how the 
product works. Also more parameters could be measured using different sensors 
but this is dependent of the client requirements that are constantly being 
evaluated. 
3.3.1 Electrocardiogram 
The electrical activity of the heart over time can be recorded by an 
electrocardiograph thus producing an electrocardiogram (ECG) [11]. 
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Electrocardiography is a fundamental part of cardiovascular assessment. It is an 
essential tool for investigating cardiac arrhythmias and is also useful in 
diagnosing cardiac disorders such as myocardial infarction [12]. 
The contraction and relaxation of cardiac muscle results from the 
depolarization and repolarization of myocardial cells. These changes are 
recorded via electrodes placed on the limbs and chest wall and are transcribed 
on to a graph to produce the ECG [12]. 
The typical elements in an EGC waveform are presented in Figure 1. These 
are the isoelectric line, a horizontal line when there is no electrical activity; 
segments, the duration of the isoelectric line between waves; and intervals, the 
time between the same segments of adjacent waves. The P-wave results from 
the depolarization of the atria. The QRS complex corresponds to the ventricular 
depolarization. The T-wave represents ventricular repolarization and the U-
wave is caused by after-potentials that are probably generated by mechanical-
electric feedback [13]. 
The PQ segment corresponds to electrical impulses transmitted through the 
S-A node, the PQ interval expresses the time elapsed from atrial depolarization 
to the onset of ventricular depolarization. The ST-T interval coincides with the 
slow and rapid repolarization of ventricular muscle. The QT interval 
corresponds to the duration of the ventricular action potential and 
repolarization. Then TP interval is the period for which the atria and ventricles 
are in diastole. The RR interval represents one cardiac cycle and is used to 
calculate the heart rate [13]. These elements are used to diagnose heart diseases. 
 
Figure 1 - Typical ECG wave [14] 
The sensor used for this application is a low-noise ECG triodes that is 
specially design for local placement and allow signal acquisition. It is designed 
to maximize the sensor performance and providing high resolution signals for 
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fine detailed analysis. It works by detecting and amplifying small electrical 
changes on the skin that are caused during the heart muscle cycle during each 
heartbeat. 
 
Figure 2 - EcgPLUX sensor [15] 
This sensor is mostly used for heart rate and stress monitoring, biometric 
verification and life monitoring. It is also suitable for research applications [15]. 
3.3.2 Temperature 
The normal temperature of a resting human is 37.0 degrees Celsius. Despite 
this, the value can vary due to an individual metabolism rate, age and time of 
the day. The higher the metabolism the higher will be the body temperature. 
Also it was proven that body temperatures are lower in the morning due to the 
rest the body received and higher at night after the day of muscular activity 
and food intake. Older people usually have lower body temperatures [16]. 
Body temperature also varies on the part of the body the measure is taken 
from. Oral temperatures are accurate and the most convenient. Axillary or 
between two folds of skin are external measurement that a take the longest and 
are very inaccurate. Rectal temperatures are the least time consuming and most 
accurate type of measurement but they are by far the least convenient [17]. 
This signal is important in order to detect as quickly as possible 
hyperthermia or hypothermia situations. Abnormal body temperature values 
can indicate disease, injury or pharmacologic activity. Clinicians can use this to 
assess infection, inflammation or antigenic responses. It can also be used as an 
indication of the efficacy of treatment [18]. 
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Figure 3 - Fora IR21 Series - Ear and Forehead Thermometer [19]. 
 
The sensor used is a FORA IR21 Series – Ear and Forehead Thermometer 
depicted in figure 3. It offers quick and convenient monitoring detecting both 
forehead and ear temperature. This thermometer has many key features such as 
are fever alert, one second measurement time, 10 values of memory capacity, a 
long battery life and it can transmit data wireless with Bluetooth [19]. 
3.3.3 Blood glucose and pressure 
Measure of blood glucose at home is usually done by people diagnosed with 
diabetes mellitius. Diabetes is likely to become one of the most prevalent and 
economically important diseases of the 21st century because of an increasing 
incidence of type 2 diabetes mellitus in the developed countries [20]. 
This disease is characterized by hyperglycemia that results from defects in 
the secretion and/or action of insulin. Generally, type 1 diabetes mellitus is 
accepted as autoimmune disease with triggering factors responsible for the 
development of autoimmunity. On the other hand, type 2 diabetes mellitus is 
associated with peripheral insulin resistance, problems in hepatic glucose 
production, abnormalities in glucose absorption and obesity. The main effects of 
the disease include long-term damage and failure of various organs [21]. It is a 
serious chronic disease that leads to a substantial reduction in life expectancy, 
decreased quality of life and increased costs of care [21]. 
In blood glucose self-monitoring technique a drop of blood is applied to a 
strip inserted in a meter. The drop of blood then produces an electrical current 
proportional to its glucose concentration. This technique has become an integral 
part of insulin treatment. It allows patients adjust their insulin dosage and helps 
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avoid hypoglycemia. This gives him a better control of his situation but there is 
not a consensus on how often patients should check their blood glucose [20]. 
Official hypertension guidelines acknowledged the value of blood pressure 
monitoring for the accurate diagnosis of hypertension. Self-monitoring has many 
advantages as it eliminates the white coat syndrome, a phenomenon in which 
patients exhibit elevated blood pressure in clinical setting but not in other 
settings due to anxiety, allows the increased number of readings and how the 
response to antihypertensive treatment is, reduces costs and improves patient 
compliance [22]. 
Systolic blood pressure has a strong tendency to increase with age, so the 
prevalence of hypertension also increase with age. Globally, high blood pressure 
accounts for more deaths than many common conditions and it is a major 
burden of disease. 
Hypertension is related with genetic and environmental factors [23]. 
Environmental factors include salt intake, weight, alcohol consumption, stress 
and diet. Control of these factors is essential in preventing and in managing 
hypertension. 
The increases of systolic and diastolic blood pressures are associated with 
different pathologies as stroke, which is one of the most devastating 
consequences of hypertension resulting in premature death or disability; 
dementia, elderly people are at risk of asymptomatic cerebral strokes that may 
lead to loss of intellectual or cognitive function and heart failure, where 
hypertension is the main cause. 
 
Figure 4 - FORA D40d - Blood glucose plus blood pressure monitoring system [24] 
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The device used to monitor blood glucose and blood pressure is FORA D40d. 
The results can be stored in memory or transmitted to a computer or the 
internet for data management. It also allows Bluetooth connectivity – used by 
OneCare Sensing – and GPRS connectivity [25]. 
3.3.4 Pulse oximetry 
Pulse oximetry is a noninvasive method for monitoring the saturation of 
oxygen in a patient. It is considered the ultimate safety monitor in anesthesia 
because it shows not only how well the patient is oxygenated but also that the 
blood is circulating [26]. 
The operating principle is that the absorption of light at two wavelengths 
differs according to the haemoglobin’s degree of oxygenation. The measuring of 
light absorption occurs at 600-750 and 850-100 nanometers. The ratio between 
the two is then computed giving the measurements of arterial blood oxygen 
saturation [26]. 
There are various types of hypoxia but the hypoxic hypoxia, which occurs 
when arterial haemoglobin oxygen saturation is low, is the only form that can 
be detected by the pulse oximeter. There are three main causes of failure of 
oxygenation of the blood by the lungs, low partial pressure of inspired oxygen, 
pulmonary causes and cardiovascular causes. Related to these causes of failure it 
is possible to associate several pathologies such as chronic bronchitis, asthma, 
pneumothorax, sleep apnea, pneumonia, emphysema, cardiac failure, amongst 
many others. An alarm is triggered when the oxygen saturation is below 95%. 
 The most obvious advantages of this technology are that it is fast, accurate 
and non-invasive and reliable. Regarding disadvantages, the inefficacy in poor 
perfusion states, in anemia, color interference, skin pigmentation and motion 
artifacts needs to be considered. 
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Figure 5 - Nonin 4100 Bluetooth enabled digital pulse oximeter [27] 
The device that accomplishes this is Nonin 4100 bluetooth enabled digital 
pulse oximeter that allows SpO2 , pulse rate and plethsmographic data to be 
transmitted through Bluetooth to the tablet used in OneCare Sensing. The 
maximum range of the device is around 9 meters (spherical radius) [28]. 
3.3.5 Respiratory parameters 
Spirometry takes measurements of the quantity of air inhaled and exhaled by 
the lungs during a certain period of time to determinate the pulmonary 
capacity. It is the most valuable test for assessment of patient with chronic 
obstructive pulmonary disease (COPD), asthma, interstitial lung diseases and 
other respiratory diseases, preoperative and occupational risk [29]. OneCare 
Sensing will assess the prevention and monitoring of COPD. 
COPD covers at least three factors: chronic bronchitis, emphysema and 
progressive obstruction of the small airways. It is characterized by slowly 
progressing, mainly irreversible airways obstruction and a decreased expiratory 
flow rate. The decreased flow rate is caused by varying degrees of airways 
obstruction and emphysema [30]. 
Spirometry measurements for the diagnosis of COPD include: forced vital 
capacity (FVC), maximum volume of air that can be exhaled during a forced 
maneuver; forced expired volume in one second(FEV1), the volume expired in 
the first second of maximal expiration after a maximal inspiration and the ratio 
between those two indicates airflow limitation and thus COPD [31]. 
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Figure 6 - Vitalograph copd-6 [32] 
One device that can be used for effective COPD screening is Vitalograph 
copd-6TM that identifies those at risk of COPD at the pre-symptomatic stage to 
allow early medical intervention and provide better clinical outcomes. It can 
screen identify those for which FEV1 is normal without the risk of false COPD 
negatives [32]. 
3.3.6 Body mass 
Body mass index (BMI) is defined as the individual’ s body mass divided by 
the square of their height given in units of kg/m2. It should be measured and 
record as any other vital sign as a practical way to identify individuals who are 
overweight or obese. Overweight is defined with a BMI between 25 and 29 
kg/m2 and obese with one greater than 30 kg/m2. Genetic and environmental 
causes are in the heart of risks of this epidemic [33]. 
Table 3 – Weight classification adapted from [33] 
Classification BMI Obesity Stage 
Underweight ≤18.5 - 
Normal 18.5 to 24.9 - 
Overweight 25.0 to 29.9 - 
Obesity 30.0 to 34.9 I 
 35.0 II 
Extreme obesity ≥40.0 III 
 
Excess weight is associated with pathologies such as stroke, type 2 diabetes, 
endometrial, breast and colon cancer and also increases the risk of liver and 
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gallbladder disease, sleep apnea, osteoarthritis and gynecologic problems such as 
infertility [33]. 
Although BMI correlates with the amount of body fat it does not 
differentiate fat from muscle. It is important to identify more factors as diseases 
associated with obesity, such as high blood pressure, physical activity and waist 
circumference as a measure of abdominal adiposity [34]. 
 
Figure 7 - FORA W310b Weight Scale [35] 
The weight scale used is FORA W310b that features high accuracy and 
many functions as Bluetooth data transmition, body weight and BMI 
measurements, conversion of weight units (Kg/st/lb) and it can store up to 135 
results [35]. 
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4 State of the art 
The state of the art given is more focused in the market of remote patient 
monitoring products. It is essential to understand how the market is structured 
in order to know how to deploy the product that is being certified in the best 
possible manner. Therefore the following chapter presents a compilation and 
review of different studies that are considered relevant to the remote patient 
monitoring and treatment (RMT) market as the state of the art. 
Firstly an introduction to some key concepts and background is given. Then 
a market overview is presented to show some facts and numbers considered 
relevant. After this the constitution of the main players, Horizon 2020 program, 
a sample of market products similar to OneCare Sensing and the difficulties and 
barriers in this market are showed. 
4.1 Introduction 
It is predicted that the patient monitoring market is going to growth 
significantly in the next years. As reported by several market studies the devices 
that measure patient’ s vital signs across the patient’ s house or hospital 
building are the fastest growing medical devices in terms of revenue earned.  
According to one of them, revenues have doubled in the last four years and it is 
expected to double in the next four. To demonstrate part of this statement, a 
growth of 23% between 2008 and 2010 was seen in the remote and wireless 
patient monitoring devices [36]. 
The European health systems differ a lot from country to country but 
despite this they have common objectives such as universality, access to good 
quality care, solidarity and equality they also share common challenges [37]. 
One that is relevant to refer is population ageing –  with the increase of this 
segment in the population there will be more people with chronic diseases that 
require routine monitoring which consequently increases healthcare costs [38]. 
Also according to the Eurostat Labor Force Survey there is going to be a lack of 
qualified personal in the area of Health and Social work such as physicians and 
nurse graduates. This factor presents a lack of human resources that will also 
contribute to the difficulty in treating the increasing ageing population with 
chronic diseases. 
In the EU the funding in healthcare rely in three different methods. The 
Beveridge model, focused in public taxation. The Bismark model, focused in 
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compulsory social insurance. And the third is based on voluntary private 
insurance that complements the social insurance. The increase of healthcare 
costs will overload these models and it is necessary to take measures in order to 
maintain a sustainable system [38]. 
The most relevant chronic diseases that are important to discuss are 
diabetes, chronic obstructive pulmonary disease (COPD) and cardiovascular 
diseases (CVD) because they are targeted by RMT and have economical 
relevance [39]. The impact of cardiovascular diseases is estimated to be 192 
billion euros a year in Europe [40]. 
Telemedicine and more specifically RMT devices aim to decrease the costs 
mentioned above, related with cutting hospital stays, deal with reduced staff 
and reduce human errors. According to the Strategic Intelligence Monitor on 
Personal Health Systems (SIMPHS) joint research center of European Union, 
RMT systems “ help patients with chronic diseases monitor vital signs (blood 
pressure, heart rate, blood glucose, weight, oxygen contents, ECG) thus 
improving the quality of care, the quality of life of the patient and prediction of 
aggravations and exacerbations of their chronic condition.”  Also it is important 
to understand what IPHS is, “ Integrated Personal Health/Care Services 
address the health and/or social care needs of individuals outside of care 
institutions and support the work of care providers in an integrated fashion: a) 
they can integrate assistance, remote monitoring of chronic diseases, wellness 
and fitness; b) they are produced as a result of integration of different 
institutional and information systems. They are personal and possibly 
personalized in the way they gather, process and communicate data (for feed-
back/action) and in terms of technological components they can include all of 
the items illustrated a) trough c)” . 
4.2 Market overview 
According to an European study, currently the remote patient monitoring 
market is fragmented, small in size and it has a lot of social, economic and 
technical barriers [41]. Despite this there are a lot of different market reports 
that have an estimation of the real size and value of RMT. 
According to Frost and Sullivan’ s the remote patient in Europe in 2009 had 
the UK with a 25% market share and Germany with 21%. Other relevant 
markets are France, Italy and Benelux [41]. 
Also from a Transparency study, “ Remote Patient Monitoring Devices 
Market –  Global Industry Size, share, Analysis, Upcoming Technologies, 
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Current Trends And Forecasts 2012-2018”  the remote patient monitoring 
market is expected to reach $556.9 million by 2016 with an annual growth of 
10% in the selected period. The largest segment of the industry is cardiac 
monitoring which will constitute about 72% of the total market. The United 
States and Europe will be the main geographical areas where this growth is 
verified [42]. 
The remote patient monitoring can be segmented in two fields, telecare and 
telehealth. Telecare provides real time monitoring of emergencies and social care 
with support from communication technology. Telehealth provides remote 
monitoring of patient’s vital signs through the use of medical devices [43]. 
Telehealth market is driven as stated before by ageing population and 
increasing of patients with chronic diseases. The need to manage patients in 
remote locations, the increase hospital expenses and decreasing number of 
physicians to assist patients are the driven forces to sustain this market. 
RMT systems contribute in the following manner: 
•  Improve healthcare outcomes and simultaneously help control costs; 
•  Help reach healthcare to remote regions and solve the problem of short 
number of health care professionals; 
•  Improve job creation and entrepreneurial activities and innovation such 
as ISA-Intellicare. 
4.3 Players 
The players active in the RMT market segment are presented in annex 1. 
This company list was adapted from annex 3 of the “ Strategic Intelligence 
Monitor on Personal Health Systems, Phase 2: Market Developments –  Remote 
Patient Monitoring and Treatment, Telecare, Fitness/Wellness and mHealth”  
presented by the Joint Research Center of the European Commission from 2013. 
The adaptation was made by analyzing the products and services of each 
company and selecting the ones that are included in the RMT definition. It was 
discovered that 9 companies where bankrupt and 24 where not active in the 
RMT market. 
The companies involved in the annex fulfill four main criteria of the study 
mentioned above: 
 They played a relevant role in the RMT market; 
 They had an European focus; 
 They covered as many products and services as possible; 
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 They covered all parts of the PHS value chain. 
Figure 8 shows the geographic distribution of the 81 RMT companies 
considered in annex 1. There are about 48 companies in Europe, 25 in the USA 
and the 8 remaining are reasonably divided by other countries.  
 
Figure 8 - Companies on the RMT market - Geographic origin 
The market players that provide hardware solution for RMT can be divided 
in four main categories [43]: 
 Medical engineering companies that demand higher quality products 
and invest significantly on staff qualifications especially R&D staff. 
 Companies that modify existing products to enable them to be used 
by laymen. Usually this is done to extend their market scope. 
 Pharmaceutical companies enter as new players since they can 
complement their product (drugs) with RMT adding more value to 
their service. 
 Original Equipment Manufacturers (OEM), companies that 
manufacture products for other companies to be repackaged and 
resold with other name and logo.  
Frost & Sullivan rated Germany and the UK as the European markets with 
the best short term opportunities regarding revenues. France and Italy also 
show good prospects and the others small markets will tend to grow. But in the 
long run it will be difficult to predict the RMT market in countries that rely in 
government subsidies since cuts on telehealth and telecare can be made. 
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4.4 Horizon 2020 
In this section the next EU funded programs will be presented in order to 
show new investment opportunities and the economic relevance regarding the 
market being depicted. 
The biggest European Union Research and Innovation program is Horizon 
2020. It has around 80 billion euros on funding available from 2014 to 2020 not 
counting with the private investment that the programs will attract. It aims to 
secure Europe’ s global competiveness and at the same time drive economic 
growth and create jobs [44]. 
Horizon 2020 is based on the societal challenges identified and shared by 
European citizens. This will put together a lot of resources and knowledge from 
different fields from a more technical approach to social sciences. The challenges 
according to the EU are [45]: 
 Health, demographic change and wellbeing; 
 Food security, sustainable agriculture and forestry, marine and 
maritime and inland water research, and the Bioeconomy; 
 Secure, clean and efficient energy; 
 Smart, green and integrated transport; 
 Climate action, environment, resource efficiency and raw materials; 
 Europe in a changing world - inclusive, innovative and reflective 
societies; 
 Secure societies - protecting freedom and security of Europe and its 
citizens. 
The challenge that is relevant to identify here is Health, Demographic 
Change and Wellbeing. It includes keeping older people active and independent 
by developing safer and effective solutions. During 2014 and 2015 the EU will 
invest around 1200 million euros only in this section of the program. 
In order to be more specific the research & innovation team duties related to 
this call will be improving the understanding of healthy ageing and disease; 
improve the ability to monitor health, prevent, detect, treat and manage 
disease; support older people to remain active and independent and test and 
demonstrate models to health and care delivery [44]. 
The full work program for the next two years can be found in “Horizon 2020 
Work Programme 2014-2015: 8. Health, demographic change and wellbeing” . In 
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the next table one can find a selection of calls, their proposition value and type 
of action that incorporate ICT and the program mentioned above. 
Table 4 - List of calls in Horizon 2020 
Calls Proposition value (M€) Type of action 
PHC 19 - 2014 
Advancing active and 
healthy ageing with ICT: 
Service robotics within 
assisted living 
environments 
3 to 4 
Reserach and 
innovation 
PHC 20 - 2014 
Advancing active and 
healthy ageing with ICT: 
ICT solutions for 
independent living with 
cognitive impairment 
2 to 3 Innovation 
PHC 21 - 2015 
Advancing active and 
healthy ageing with ICT: 
Early risk detection and 
intervention 
3 to 4 
Reserach and 
innovation 
PHC 25 - 2015 
Advanced ICT systems 
and services for 
Integrated Care 
3 to 5 
Reserach and 
innovation 
PHC 26 - 2014 
Self-management of 
health and disease: 
citizen engagement and 
mHealth 
3 to 5 
Reserach and 
innovation 
PHC 27 - 2015 
Self-management of 
health and disease and 
patient empowerment 
supported by ICT 
3 to 5 
Pre-commercial 
procurement co-
fund actions 
PHC 28 - 2015 
Self-management of 
health and disease and 
decision support systems 
based on predictive 
computer modelling 
used by the patient him 
or herself 
3 to 5 
Reserach and 
innovation 
PHC 29 - 2015 Public procurement of 
innovative eHealth 
services 
1 to 5 
Public 
procurement of 
innovative 
solutions co-
fund actions 
PHC 30 - 2015 
Digital representation of 
health data to improve 
disease diagnosis and 
treatment 
3 to 5 
Reserach and 
innovation 
PHC 34 - 2014 
eHealth interoperability 
1 
Coordination 
and support 
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Calls Proposition value (M€) Type of action 
actions 
HCO 1 - 2014 
Support for the 
European Innovation 
Partnership on Active 
and Healthy Ageing 
1 to 2 
Coordination 
and support 
actions 
HCO 2 - 2014 
Joint Programming: 
Coordination Action for 
the Joint Programming 
Initiative (JPI) "More 
Years, Better Lives - the 
Challenges and 
Opportunities of 
Demographic Change" 
1 to 2 
Coordination 
and support 
actions 
 
4.5 Marketed products 
This section will present some products currently being marketed that share 
one or more functions with OneCare Sensing. This is not supposed to be an 
extensive list nevertheless it can provide some useful information regarding the 
competition that exists in the RMT market today. 
 
Alive Heart and Activity Monitor –  This is a wireless health monitoring 
system for consumer health that can screen, diagnose and manage chronic 
diseases. The applications for the product include management of atrial 
fibrillation, heart failure, cardiac rehabilitation and fitness monitoring. The data 
gathered is transmitted wireless by Bluetooth to a mobile phone, computer or 
central monitoring center. Then it is available for consultation via internet [46]. 
 
Figure 9 - Alive Heart and Activity Monitor [46] 
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Aipermon Telemonitoring –  A complete telemonitoring solution that is 
presented in the figure below. The AiperMonitor PC Software allows the access 
of the activity, weight, blood pressure, glucose, insulin and state of the health 
data [47]. The system is built with different modules that function togheter in 
order to automatically transfer the data to and hospital, medical call center or 
physicians. 
 
 
Figure 10 - Aipermon Telemonitoring [47] 
 
Beurer’s One 4 ALL – Beurer sensor’s allows the data gathered to be transferred to a 
PC and smarthphones. The PC software enables to analyze the body values more 
closely and it has many functions that allow conveniently exporting or sending data to a 
doctor. The HealthManager APP as the same functions of the pc software [48]. 
 
 
Figure 11 - Beurer’ s One 4 ALL [48] 
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BodyTel System – Is a telehealth product that supports and diagnoses patients with 
home chronic illnesses advised by healthcare providers. It uses sensors with an 
integrated Bluetooth module to measure blood glucose levels, arterial pressure and 
weight. Then data is sent to a patient’s cell phone or tablet and posteriorly to a database 
to be consulted by others. The system also as an alarm option that is triggered when 
physiological parameters fall under a certain threshold [49]. 
 
 
Figure 12 - BodyTel System [49] 
 
Bosch Telehealth system – Each day there is a new session where the patient can 
gather his vital signs, review sympthoms, take surveys, have an educational coaching 
and reinforcement of positive behavior. The vital signs are gathered with a wireless 
sphygmomanometer and a pulse oxymeter. The system can access depression, CHF and 
COPD. The system can send data to a healthcare provider for further assessment [50]. 
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Figure 13 - Bosch Telehealth system [50] 
 
Dyna-Vision Telemonitoring System –  Designed for remote monitoring of 
ECG, SpO2, temperature, respiration rate and blood pressure. It transmits the 
values in real time to a server and various alarms can be defined for each 
parameter. Data is stored in the PC and in the cloud to generated PDF reports 
[51]. 
 
 
Figure 14 - Dyna-Vision Telemonitoring System [51] 
 
BodyGuardian Remote Monitoring System –  Where the patients wear a 
control unit that transmits data by wireless to a smartphone device. Then data 
is available in a Preventice CarePlataform, a cloud-based plataform that collects 
real-time data and delivers this information to healthcare professsionals. It 
monitors patient ECG, respiration rate, activity level and body position [52]. 
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Figure 15 - BodyGuardian Remote Monitoring System [52] 
4.6 Difficulties and barriers 
The main barriers reported by market players mentioned in the JRC 
Scientific and Policy Reports, “ Market Developments –  Remote Patient 
Monitoring and Treatment, Telecare, Fitness/Wellness and mHealth”  are the 
following: 
 Lack of reimbursement –  A major obstacle on the market because of 
the costs associated with the technology. 
 Buyers’  fragmentation –  The diversity of healthcare financial 
structure in Europe results in decentralized and different ways 
companies sell their products and services. 
 Difficult to be accepted by health care organizations –  There is 
resistance from health care providers to accept RMT 
products/services.  
 Constrains to market scale –  The buyers’  fragmentation mentioned 
before is reflected in a difficult escalation of the market. 
The barriers identified by individuals in the health care systems or by 
neutral third party experts are: 
 Unfavorable structure of incentives –  The overall financial incentives 
structure in EU countries run against RMT. There are two models, 
fee for service or capitation. Fee for service pays the fee for services 
the hospital receives and since RMT aims to keep patients out of the 
hospital this is not a good model. In the capitation model usually 
general practitioners are paid for managing a set of patients and they 
see RMT service as and extra an unpaid load. 
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 Where RMT belongs –  There is much talk about the importance of 
this form of care but politicians and policy makers need to implement 
measures to adopt RMT. 
 Lack of evidence, awareness, education –  There is a lot of evidence 
supporting RMT but the results are not conclusive. More work in 
raising awareness and education needs to be done not only for 
physicians but also patients that will use this technology.  
 Strategic leadership for structural change –  There is a need for 
strategic leadership and decision for making the delivery of RMT 
more efficient and effective. 
To sum up the main restrains in the market are the lack of common 
European standards, high costs of deployment of the technology, lack on 
information on funding and reimbursement and the resistance to IT from 
healthcare professionals. 
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5 Medical device certification in EEA and other 
European countries 
In the following chapter it is introduced the regulatory framework for the 
product OneCare Sensing and the most efficient way to obtain CE marking in 
order to market this product in Europe. This is the most detailed chapter in the 
thesis since all the practical work made in the internship falls under this scope. 
5.1 CE marking 
The CE mark in a product is a manufacturer’ s claim that it meets the 
essential requirements of the applicable directive and it is a legal mandatory 
requirement to place a medical device in the European market [53]. The 
countries that recognize this marking are in the European Economic Area, 
Switzerland, Macedonia and Turkey. The EEA includes the 28 member states of 
the EU plus the european free trade association; Switzerland regonizes CE 
marking as national law; Macedonia and Turkey are candidates to become 
European Union members. 
CE marking is not an indicator that a product was made in Europe, it only 
states that the product was assessed before being placed in the market 
according to the legal applicable requirements enabling it to be sold here [53]. 
 
Figure 16 - CE marking logo [54] 
 
5.1.1 Key players 
The key players involved in the CE marking process are the following: 
- Manufacturers, responsible for manufacturing activities related to a device 
that is being placed on the market under the manufacturers’  name [55]. 
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- Competent authorities, national authority that assures the medical devices 
sold in that country satisfy the essential requirements established in the 
directive –  in Portugal is INFARMED, Autoridade Nacional do Medicamento e 
dos Produtos da Saúde I.P. 
- Notified Bodies, third party organizations that carry out conformity 
assessments in European harmonized standards or European Technical 
Assessment. Their tasks include product certification, factory production control 
certification and determination of the product-type on the basis of type testing 
[56]. 
- Authorized representative, is a natural or legal person established in the 
EU designated by a non-European manufacturer to act on its behalf regarding 
some tasks designated by the directives [57]. 
- Distributors, natural or legal person who makes available medical devices 
to the end user [58]. 
- Laboratories, they perform analysis and evaluation of trials following 
certain standards to guarantee the safety of the device. 
5.2 Process overview 
In figure 17 are presented the necessary steps in order to obtain CE marking 
for OneCare Sensing. These steps could apply to other products but here they 
are specific to the product being analyzed. They will be discussed more 
specifically in the next section. 
 
Figure 17 - Steps to obtain CE marking 
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5.3 Identify applicable directives 
Rules relating to the safety and performance of medical devices in the EU 
consist of 3 Directives:  
 Directive 90/385/EEC regarding active implantable medical devices;  
 Directive 93/42/EEC regarding medical devices reviewed and 
amended by the 2007/47/EC; 
 Directive 98/79/EEC regarding in vitro diagnostic medical devices.  
They aim ensuring a high level of protection of human health and safety and 
the good functioning of the health market. Each one of these directives is 
transposed to national law by their members. In Portugal the national law for 
the directive 93/42/EEC is Decreto-Lei n.º 273/95, de 23 de Outubro . In a 
very superficial analysis it was verified that this law is a simple translation of 
the directive. 
After being aware of these directives it could be simple to conclude that 
directive 93/42/EEC regarding medical devices is the one applicable to our 
product. But in order to be sure it is essential to qualify if OneCare Sensing is, 
in fact, a medical device. 
In order to have a proper qualification of the product it is important to 
understand what a medical device is. To do this one must refer to Article 1.2(a) 
of Directive 93/42/EEC [59] known as the medical devices directive. By their 
definition, 
“  (a) ►M5 ‘ medical device’  means any instrument, apparatus, appliance, 
software, material or other article, whether used alone or in combination, 
including the software intended by its manufacturer to be used specifically for 
diagnostic and/or therapeutic purposes and necessary for its proper application, 
intended by the manufacturer to be used for human beings for the purpose of: 
◄ 
— diagnosis, prevention, monitoring, treatment or alleviation of 
disease, 
— diagnosis, monitoring, treatment, alleviation of or compensation 
for an injury or handicap, 
— investigation, replacement or modification of the anatomy or of 
a physiological process, 
— control of conception, and which does not achieve its principal intended 
action in or on the human body by pharmacological, immunological or 
metabolic means, but which may be assisted in its function by such means;“  
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After being aware of this definition it was read the MEDDEV 2.1/6 January 
2012 - Qualification and Classification of stand alone software [60] in order to 
qualify the product correctly. 
Regarding chapter 1 “ Definitions and abbreviations”  in the above guideline, 
the product OneCare Sensing is a standalone software once the tablet where the 
software is implemented is not a medical device. 
By analyzing “ Figure 1: A decision diagram to assist qualification of 
software as medical device”  of MEDDEV 2.1/6 [60] the decision steps made 
were, 
 
Question.1. “ Is the software a computer program? (cf. ISO/IEC 2382-1)”  
Answer.1. The software used is indeed a computer program. 
Q.2. “ Is the software incorporated in a medical device?”  
A.2. No. The tablet where the software is implemented is not a medical 
device. 
Q.3.” Is the software performing an action different from storage, archival, 
lossless compression, communication or simple search?”  
A.3. Yes. The software is providing alarms based on the data acquired. 
Q.4. “ Is the action for the benefit of individual patients?”  
A.4. Yes. View intended use. 
Q.5. Is the action for the purposes defined in art 1.2a of MDD?”  
A.5. Yes. View definition of medical device. 
It is concluded that OneCare Sensing with alarms is covered by medical 
device directives. 
 
Also, using the same guide, in annex 3.1. about the Clinical Information 
Systems –  CIS / Patient Data Management Systems –  PDMS [60], 
 
“ Modules that are intended to provide additional information that 
contributes to diagnosis, therapy and follow-up (e.g. generate alarms) are 
qualified as medical devices.”  
 
With this information it is justified that OneCare Sensing with alarms is a 
medical device. 
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5.4 Medical device classification 
Medical device classification is divided in four risk classes showed in figure 
18. Determine product classification is one of the most important tasks of the 
work because it dictates which are the next steps to follow in order to obtain 
CE marking. These steps include if it is needed the intervention of a notified 
body and the way compliance is achieved within the directive. 
 
Figure 18 - Medical device class's according to risk 
The classification criterion is based on a set of 18 rules presented in Annex 
IX of the MDD. In order to establish a proper classification of the product it is 
important to understand its intended use, characteristics and the technology 
behind it. 
In accordance with section 1.4 of Annex IX of the European Directive 
93/42/EEC [59], stand-alone software is considered to be an active medical 
device. OneCare Sensing with alarms is, therefore, due to its characteristics an 
active, non-invasive, medical device. The rules applied to active medical devices 
in the previous annex are rules 9, 10, 11 and 12. To be more specific only rule 
10 is pertinent to OneCare Sensing: 
Rule 10 - “ Active devices intended for diagnosis are in Class IIa: (…) 
- if they are intended to allow direct diagnosis or monitoring of vital 
physiological processes, unless they are specifically intended for 
monitoring of vital physiological parameters, where the nature of 
variations is such that it could result in immediate danger to the patient, 
for instance variations in cardiac performance, respiration, activity of 
CNS in which they are class IIb. (…)”  
Since this is a very vast definition, a guide on the applicability of the rule 
was followed. These guidelines are the Guidance MEDDEVs that aim to 
promote a common approach by manufacturers to the medical device directives. 
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By the intended use of the device and MEDDEV 2.4/1 Rev.9 June 2010 –  
Classification of medical devices, Chapter 4.2. General explanation of 
rules/pratical issues/examples, rule 10, note 1 [61], 
“ Note 1: Vital physiological processes and parameters include, for example 
respiration, heart rate, cerebral functions, blood gases, blood pressure and body 
temperature. Medical devices intended to be used for continuous surveillance of 
vital physiological processes in anesthesia, intensive care or emergency care are 
in Class IIb, whilst medical devices intended to be used to obtain readings of 
vital physiological signals in routine check ups and in self-monitoring are in 
Class IIa. A thermal imaging device intended to monitor blood flow is not 
considered to be a temperature measuring device.”  
It is concluded that OneCare Sensing with alarms is classified as an active 
medical device of Risk Class IIa, based on Rule 10 (Active devices intended for 
direct diagnosis) of Annex IX of the European Directive 93/42/EEC. 
The table below tailors the rules of Annex IX of European Directive 
93/42/EEC with respect to the risk classification of OneCare Sensing. 
Table 5 - Rules of Annex IX of MDD applied to OneCare Sensing 
Nr. Rule Applicability 
I. – 1.6 Active device for diagnosis Yes 
II. – 3.2 
Rule 
10 
Active devices intended for diagnosis are in 
Class IIa: 
Yes 
 If they are intended to supply energy which 
will be absorbed by the human body, except for 
devices used to illuminate the patient’s body, in 
the visible spectrum. 
No 
 If they are intended to image in vivo 
distribution of radiopharmaceitucals. 
No 
 If they are intended to allow direct 
diagnosis or monitoring of vital physiological 
processes, unless they are intended for 
monitoring of vital physiological parameters, 
where the nature of variations is such that it 
could result in immediate danger to the 
patient, for instance variations in cardiac 
Yes, although 
the software is 
not used for 
direct diagnosis 
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performance, respiration, activity of CNS in 
which case they are in Class IIb. 
 Active devices intended to emit ionizing 
radiation and intended for diagnostic and 
therapeutic interventional radiology including 
devices which control or monitor such devices, 
or which directly influence their performance, 
are in Class IIb. 
No 
 
5.5 Conformity assessment route 
After the classification of the product the manufacturer must choose the 
conformity assessment procedure that is laid out in article 11 of the MDD. For 
a class IIa device there are four possible ways to demonstrate the conformity 
with the directive: 
 Annex VII + Annex IV (EC verification); 
 Annex VII + Annex V (production quality assurance); 
 Annex VII + Annex VI (product quality assurance); 
 Annex II (full quality assurance) with point 4 of the annex not 
applicable. 
The route chosen was the Full quality assurance (Annex II) with the 
exemption of point 4. The next section will show how its implementation can be 
achieved inside the company. 
5.5.1 Compliance with annex II of the MDD 
The compliance route with annex II of the directive 93/42/EEC was chosen. 
This ensures the application of a quality system approved for the design, 
manufacture and final inspections of the product and must be audited by a 
notified body after its implementation. This annex is divided in the three next 
sections. 
 
Quality system 
This section refers that the manufacturer must apply to the notified body to 
assess the quality system. This application must ensure that the product 
complies with the directive since design to production.  These elements such as 
documentation, data, records, etc are presented in this section. Also refers the 
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importance of having a post-production phase to implement necessary corrective 
actions if the product malfunctions or has performance issues. 
 
 Surveillance 
The manufacturer must allow notified body inspections and supply all the 
necessary information to check if the obligations imposed are being fulfilled. 
  
Administrative provisions 
The documentation such as the declaration of conformity, quality systems 
manuals and technical file must be available for the national authorities for at 
least five since the product manufacturer date. 
5.6 Implement quality system according to ISO 13485:2003 
In order to implement the quality system mentioned above the manufacturer 
could use ISO 13485:2003. This quality management system, specific for medical 
devices, is described in one of the following sections. It is important for a 
manufacturer to use this standard because of regulatory purposes and to provide 
better quality for their products and services. 
5.7 Technical file 
The requirements for the technical file are spread in the annexes of the 
directive so it was used the recommendation “2.5.1 Conformity assessment 
procedures; General rules from NB-MED” [62] in which a recommended 
structure for the documentation is given. 
This structure was adapted since some details related with the technical 
point of view were not applicable to OneCare Sensing.  The file compiled can be 
viewed in annex 2 and the index is shown below: 
1 Introduction 
1.1 Objectives 
1.2 Manufacturer 
1.3 OneCare Sensing Research & Development 
1.3.1 OneCare Sensing Related Scientific Papers 
1.4 Regulatory frame of reference 
1.5 References 
1.5.1 Applicable Documents 
1.5.2 Reference Documents 
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2 Product Description 
2.1 General description of the device 
2.2 Intended Use 
2.3 Description of the accessories which are intended by the 
manufacturer to be used in combination with the device 
2.4 Classification of the device 
3 Technical Requirements 
3.1 Identification of technical requirements 
3.2 Essential requirements checklist 
3.3 Standards applied 
4 Design 
4.1 Risk analysis results 
4.2 Specifications of the checks, tests and trials that are intended to 
be carried out as part of routine production 
4.3 Performances and compatibilities intended by the manufacturer 
4.4 Labelling, including any instructions for use 
4.5 Results of Bench Testing 
4.6 Clinical evaluation 
4.7 Documentation and reporting of Design Changes 
5 Administrative details 
5.1 Declaration of conformity 
5.2 Application for Conformity Assessment 
5.3 Declaration that no other Notified Body is used in Conformity 
Assessment 
5.4 Notified Body Decisions and Reports 
5.5 Manufacturer’ s undertaking on procedure to review post-
production experience 
6 Annexes 
Because of the relevance of some of these points such as section 3 –  
Technical Requirements, section 4.1. Risk analysis and 4.6 Clinical evaluation 
they will be addressed individually through this document. 
 
5.8 Appoint authorized representative 
If a company does not have presence in the EU, which is not the case of ISA, 
the directive for medical devices mandates that a European Authorized 
Representative (EC Rep) located in Europe must be appointed. Their tasks are 
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only of administrative nature and it is the manufacturer responsibility to assure 
compliance according production and technical documentation [63]. The EC Rep 
should be consider as a bridge that establishes communication between the 
company that wants to market the product and the European regulatory 
authorities. 
5.9 Audit by a notified body 
The implemented quality system in the company and the technical file must 
be audited by a Notified Body in order to verify that they comply with the 
directive. After the successful audit the Notified Body will issue a CE certificate 
[64]. 
5.10 Register product with competent authorities 
Some countries such as the UK and Italy require registration of the medical 
product with the Competent authorities. They should be contacted before the 
marketing of the product in order to see if this step is necessary. A list with the 
contacts of the various authorities is provided in [65]. When the device does not 
function properly the competent authority is responsible to remove it from the 
market. 
5.11 EC declaration of conformity 
A CE declaration of conformity must be prepared by the manufacturer to 
sell medical devices in Europe. A template for this declaration is presented in 
annex 3. The elements included are [66]: 
 Name of the device; 
 Manufacturer’s name and address; 
 Name of company quality management representative; 
 Name and identification number of the notified body; 
 Name, address and phone number of European Autorized 
Representative (if applicable); 
 CE Marking certificate number; 
 Conformity assessment route to compliance, classification of the 
product and rule(s) number(s); 
 Standards applicable; 
39 
 Name and signature of a senior management representative and date 
signed. 
After this the manufacturer is able to affix CE marking to the product. It is 
important to mention that usually the CE certificates issued by the notified 
bodies have a validity of three years and ISO 13485:2003 certification must be 
renewed annually. There is also an annual audit from the notified body and if 
the company fails to pass CE marking privileges are revoked. 
5.12 Overview of contact with notified bodies 
In the official website of the European Commission and part of Europa – the 
official EU website is located the list of notified bodies that apply the legislation 
93/42/EEC Medical devices [67]. By October of 2013 it contained 76 entities. 
This list provides useful information as the body type, name and country.  
It was made a file presented in annex 6 with the information from above plus 
the contacts used in the process of medical device certification. After this five 
companies where excluded from our list because the contact with them could 
not be made. 
In the beginning of the internship the notified bodies where contacted 
individually by email in order to respond to some questions that showed up in 
the course of the work – information about the device was also provided. These 
where, 
1. We have two types of solutions. One is OneCare Sensing with and 
without alarms. Are they both medical devices? 
2. Which guidelines do you recommend in order to do the classification 
of the device? 
3. Is the international standard IEC 62304 the only one applicable for 
this situation? 
4. Which is the duration from submission of required registration 
documents until approval for CE marking is officially granted by your 
Notified Body? How much will this process cost? 
The response rate was about 40% and the content varied. From these 
responses it was found that 4 companies were not able to work in the scope of 
medical software certification. Despite classification of the device was not 
questioned some notified bodies provided their opinion on the subject. 
Regarding question 1,  
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Figure 19 – Notified bodies opinion on qualification and classification of OneCare Sensing 
without alarms 
 
Figure 20 – Notified bodies opinion on qualification and classification of OneCare Sensing 
with alarms 
Regarding question 2, the guidelines recommended where,  
 MEDDEV 2.4/1 - Classification of medical devices;  
 MEDDEV 2.1/6 - Qualification and Classification of standalone 
software;  
 Manual on borderline and classification in the community regulatory 
framework for medical devices; 
 Recommendation NB-MED/2.2/Rec4 – Software and medical devices; 
Regarding question 3, the most relevant international standard applicable to 
this device where, 
 IEC 62304 – medical device software –software life cycle processes; 
 ISO 13485:2012 – Medical Devices – Quality Management Systems; 
 ISO 14971:2012 – Risk Management system for medical devices. 
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Regarding question 4, the average cost and duration from submission to 
approval for CE marking is presented, 
Table 6 - Review of notified bodies CE marking costs 
 Cost (€) Duration (weeks) 
Max 5000 24 
Min 3000 8 
 
It is important to refer that it was necessary to provide more information 
about the process in order to have a more specific idea on the duration and 
costs but it was not available at the time. Also the costs presented in the table 
do not include ISO 13485:2003 certification. 
5.13 Essential requirements 
An important step in order to obtain CE marking is the compliance with the 
essential requirements of the directive. These requirements are laid out in 
Annex I of the medical devices directive and they describe safety objectives of 
the device [59]. 
The structure of the requirements is the following: 
 General requirements 
 Requirements regarding design and construction 
o Chemical, physical and biological properties; 
o Infection and microbial contamination; 
o Construction and environmental properties; 
o Devices with a measuring function; 
o Protection against radiation; 
o Requirements for medical devices connected to or equipped 
with an energy source; 
o Information supplied by the manufacturer. 
Some of these requirements are not applicable to medical software so it is the 
manufacturer responsibility to assess this. All the requirements are mandatory 
unless they are not applicable. 
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In order to assess compliance the company should use a checklist that 
contains the essential requirements that identified those applicable and not 
applicable. For those applicable it should also contain the standards that could 
be use and the technical documentation necessary to ensure compliance [62]. 
The essential requirements checklist for the product OneCare Sensing can be 
found in annex 2. 
5.14 Clinical evaluation 
Clinical evaluation is an important step to obtain CE marking and it is part 
of the mandatory essential requirements contemplated in article 6a of annex I of 
the MDD. It also refers the annex X that is specific for clinical evaluation. 
Clinical evaluation is essential in order to demonstrate that safety and 
performance requirements of the device are achieved [68]. 
Since the law is not very specific, in order to comply with this part of the 
directive a guide of the Co-ordination of Notified Bodies Medical devices was 
used [68].  
Clinical evaluation is defined as, “the process by which clinical data from all 
selected sources (literature, results of clinical investigations and other) is 
assessed to establish conformity of the device with the pertinent essential 
requirements of the Directive, and to demonstrate that the device performs as 
intended by the manufacturer. The outcome of this process is a report which 
includes a conclusion on the acceptability of risks and side effects when weighed 
against the intended benefits of the device.” 
There are three options that can be chosen in order to do the clinical 
evaluation, these are: 
 Literature route, based on the relevant scientific literature. 
 Clinical investigation route, based on the results of clinical 
investigations made. 
 Combination on the previous two statements. 
The manufaturer is responsible to decide which one of these routes is most 
pertinent in order to demonstrate conformity with the directive. It was decided 
that for the product OneCare Sensing the literature route was the most 
appropriate to follow. 
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Literature route 
This route consists in a review of the relevant scientific literature. It is 
recommended that the compilation should be related with the hazards identified 
in the risk analysis, include favourable and unfavourable data, other type of 
scientific data such as bench testing and assessment of compliance with 
technical standards and for simple or well-established devices it should include 
experts’ opinions regarding the device. Since this type of technology is not weel 
establish the last item is excluded. 
A written report containning the clinical evaluation is required. The one 
elaborated for the product OneCare Sensing is presented in annex 7. 
45 
6 Normative framework 
The medical devices directives specify their essential requirements in very 
general terms, standards are guides for the manufacturer to help achieve 
compliance. They provide a technical and legal interpretation of the 
requirements [69]. 
The essential requirements of the directive where analyzed and a list of the 
standards applicable to OneCare Sensing was compiled. These are: 
 EN ISO 9001:2008 –  Quality management systems –  Requirements; 
 EN ISO 13485:2003 –  Medical devices –  Quality management 
systems –  Requirements for regulatory purposes; 
 EN ISO 14971:2007 –  Medical devices –  Application of risk 
management to medical devices 
 EN IEC 62304:2006 –  Medical device software –  Software life cycle 
processes 
6.1 EN ISO 9001:2008 
ISA-Intellicare has currently implemented a quality management system 
based on ISO 9001:2008. This standard is used when an organization needs to 
provide products that meet customer and regulatory requirements; and to 
enhance customer satisfaction through the application of the system. The 
requirements of the standard are generic and intended to be applicable to all 
organizations regardless of their size, type or product/services provided [70]. 
 
Figure 21 - NP EN ISO 9001:2008 Certification that could be obtained by ISA-Intellicare 
[71] 
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6.2 EN ISO 13485:2003 
This European standard provides means for which a manufacturer can 
demonstrate conformity with the requirements of Directive 93/42/EEC on 
medical devices. It specifies requirements for a quality management system for 
the design, development, production, installation and servicing of medical 
devices or related services [72]. 
The objective of the standard is to facilitate harmonized medical device 
regulatory requirements for quality management systems. ISO 13485 is 
considered as an extension of ISO 9001 but it has some particular requirements 
for medical devices and exclusions of requirements that are not considered 
appropriate [72]. 
This quality management system was partly implemented in ISA-Intellicare 
and could be certified when the organization finds it more appropriate. It is 
recommended to perform an internal audit before the submission to the 
certification to avoid non conformities.  
 
Figure 22 - ISO 13485:2003 Certification that could be obtained by ISA-Intellicare [73] 
 
6.3 EN ISO 14971:2007 
This International standard provides manufacturers with a framework to 
manage the risks associated with the use of medical devices. Primarily risks 
related with patients but also operators, other people, equipment and the 
environment. 
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Figure 23 - Definition of risk 
This standard specifies a process for the manufacturer to identify hazards, 
estimate and evaluate risks associated with these hazards, control the risks and 
monitor the effectiveness of that control related to a medical product during 
their life-cycle [74]. The risk analysis and the procedure written based in this 
standard are presented in annex 4 and 5, respectively. 
6.4 EN IEC 62304:2006 
This standard is applied to the development and maintenance of medical 
device software. It defines the life cycle requirements for the software and sets 
processes, activities and tasks providing a common framework for medical device 
software life cycle processes [75]. 
Under this standard it is assumed that the software is developed and 
maintained within a quality management system and a risk management 
system.  
The norm focus is in the processes for development, maintenance, risk 
management, configuration management and problem solution of medical 
software. These are depicted in the figure below: 
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Figure 24 - Overview of software development processes and activities [76] 
 
6.5 ISO 9001:2008 VS ISO 13485:2003 
6.5.1 General 
The purpose of this chapter is to present the fundamental differences 
between the quality management systems based on ISO 9001:2008 and ISO 
13485:2003. This is relevant because ISA is currently ISO 9001:2008 certified 
but in a near future also wants to be ISO 13485:2003 certified in order to 
demonstrate the ability to provide medical devices and related services that 
meet customer and regulatory requirements. 
The previous two standards where analyzed and compared in order to 
identify the gaps between the two of them. After this the necessary measures to 
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comply with ISO 13485:2003 where identified and some implemented (view 
annex 8). 
The next figure presents the model for a quality management system 
following ISO 9001:2008. This model follows a process approach in which the 
main processes are: 
 Quality management system 
 Management responsibility 
 Resource Management 
 Product realization 
 Measurement, analysis, improvement 
The main input for this system is customer requirements and the output is 
customer satisfaction. These processes are common to both standards but in 
each one there are differences that will be addressed during this chapter. 
 
Figure 25 - ISO 9001:2008 process approach [77] 
Despite ISO 13485:2003 is a standalone standard it is based on ISO 
9001:2008. This means that a lot of requirements of ISO 9001:2008 are also 
presented in the standard of quality management systems for medical devices. 
The main objective of ISO 13485:2003 is to facilitate harmonized medical 
device regulatory requirements for quality management systems [72]. Because of 
this, it includes new requirements and excludes others presented in ISO 
9001:2008 that are not appropriate for regulatory requirements. 
It should be noted that the specific standard requirements and company 
documentation are not presented in this thesis. This chapter represents only an 
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opinion of the author regarding the standards and what it is observed in the 
industry taking ISA as a general example. 
6.5.2 Quality management system 
The requirements for the quality management system are presented in the 
next figure. The general requirements are fundamentally the same in both 
standards and their implementation is usually verified during an audit. 
The fundamental differences are in the documentation requirements. To 
comply with 13485:2003, documentation specified by national and regional 
regulations regarding the medical product/service should be included. 
Documentation that defines the complete manufacturing process, installation 
and servicing should also be maintained. 
The Quality Manual must include all the exclusions and non-applicable 
requirements with a detailed justification. A procedure with the structure of the 
documentation used in the quality management system must also be provided.  
Regarding the control of documents in ISO 13485:2003 it is necessary not 
only to approve documents prior to issue but also to review them when 
necessary. This can be demonstrated in an operational procedure made 
specifically for the control of records where it can also be defined the period for 
which a copy of the documents is obsolete. 
The control of records adds a requirement for which the period of time that 
these records must be maintained. 
 
Figure 26 - Quality management system requirements 
6.5.3 Management responsibility 
The requirements for the management responsibility are presented figure 27. 
Regarding management commitment, customer focus and quality policy the 
requirements are essentially the same with the difference that in ISO 13485:2003 
the focus is in maintaining the effectiveness of the quality system and not 
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improving it as it is presented in ISO 9001:2008. These are usually checked 
during an audit. 
The planning regarding management responsibility is the same in both 
standards. Concerning responsibility and authority it should be noted that 
sometimes regulations require specific personnel for certain activities. The 
management representative should also ensure the awareness of customer 
requirements AND regulatory requirements - which is not required in ISO 
9001:2008. Internal communication presents the same methods of action. 
Management review is different in the way it adds an input for the new or 
revised regulatory requirements and as a consequence one of the outputs will 
not focus on improving the effectiveness of the quality management system 
processes but in maintaining their efficacy. 
 
Figure 27 - Management responsibility requirements 
6.5.4 Resource management 
The requirements for the resource management are presented in the next 
figure. The provision of resources in ISO 13485:2003 is focused in meeting 
regulatory, customer requirements and maintain the effectiveness of the quality 
system. 
The management of human resources is the same in both standards but one 
must consider that in ISO 13485:2003 the regulations could require documented 
procedures for identifying training needs. 
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Regarding the standard for medical devices, the infrastructure includes the 
necessity of established documented procedures for maintenance activities when 
they can affect product quality. And in the work environment there are specific 
requirements that must be followed in order to be sure that the product quality 
is not affected by it. 
 
 
Figure 28 - Resource management requirements 
6.5.5 Product realization 
The general requirements for the product realization are laid in the figure 
below. The planning of product realization is similar in both standard but in 
ISO 13485:2003 the organization shall establish documented requirements for 
risk management following ISO 14971:2007 as it is presented in annex 4 and 5 
throughout product realization. 
Regarding customer related processes, the determination of requirements 
related with the product are the same in both standards. The review of 
requirements related to the product requires that product requirements should  
not only be defined but also documented. In customer communication it is also 
necessary to add advisory notices –  those are explained in the next section. 
Design and development planning should be presented in documented 
procedures elaborated by the organization. Also besides review, verification and 
validation at each design and development stage, design and transfer activities 
must be considered. These ensure that design and design and development 
outputs are verified before final product specifications. 
In ISO 13485:2003 design and development inputs add safety requirements 
according to the intended use and the outputs of risk management that should 
be reviewed and approved. The outputs are the same as in ISO 9001:2008 but 
records must be maintained. 
Design and development review must include other specialized personnel but 
essentially this part, design and development verification, validation and control 
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of design and development changes are the same in both standards. In 
validation, there is a need for clinical evaluations and/or evaluation of 
performance of the medical device (annex 7). 
In the purchasing process it is essential to assure that the purchased product 
complies with specified purchased requirements established in documented 
procedures. Also, for reasons of traceability the organization shall maintain 
relevant purchasing information for a medical product. Records of the purchased 
verification shall be maintained. 
Regarding control of production and service provision, the general 
requirements are pretty similar in both standards but in ISO 13485:2003 more 
documented procedures are needed in implementation of labeling and mapping 
and work instructions. Also new requirements concerning cleanliness of product 
and contamination control, installation activities, servicing activities and 
particular requirements for sterile medical devices are given.  
The general requirements of validation of processes for production and 
service provision in both standards are essentially the same but in ISO 
13485:2003 it is necessary to establish documented procedures and maintain 
records of these. Also new requirements regarding sterile medical devices are 
added but they do not apply to OneCare Sensing. Identification and traceability 
are stricter in ISO 13485:2003. It demands documented procedures for 
identification and to distinguish from conforming product and status 
identification through production, storage, installation and servicing. Customer 
property includes intellectual property and confidential health information for 
medical devices. The preservation of property must include documented 
procedures and work instructions that include identification, handling, 
packaging, storage and protection. 
Concerning control of monitoring and measuring devices both standard have 
the same approach but for ISO 13485:2003 there is a need to establish 
documented procedures to ensure the requirements are meet. 
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Figure 29 - Product realization requirements 
  
6.5.6 Measurement, analysis and improvement 
The requirements for the measurement, analysis and improvement are 
presented in the next figure. The general requirements are similar in both 
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standards but 13485:2003 is focused in maintaining the effectiveness of the 
quality management system and not improving it. Also some national or 
regional regulations may require documented procedures for implementation and 
control of statistical techniques. 
Regarding the feedback of monitoring and measurement it should be 
implemented a procedure to provide warnings of quality problems and for input 
of corrective and preventive action processes which is not required in ISO 
9001:2008 but it is already implemented in ISA. The internal audit and the 
monitoring and measurements of processes are the same in the standards. The 
monitoring and measurement of product is almost the same with the difference 
that documented procedures need to be implemented to monitor and measure 
the characteristics of the product.  
Concerning the control of nonconforming product there must be a procedure 
to deal with this. In ISO 13485:2003, the organization must ensure that 
nonconforming product is accepted by concession only if regulatory 
requirements are met. Also if the product needs to be reworked, the company 
needs to document this procedure. 
In the analysis of data ISO 13485:2003 adds the need for a documented 
procedure and maintain records of the results of data analysis. This could 
demonstrate the suitability and effectiveness of the quality system and access if 
improvements can be made. 
There is a big difference in the standards regarding the improvement. This is 
the addition of advisory notices that include removals from the market, 
corrective actions and product recalls. The notices are issued to provide 
information and/or to advice on what action should be taken in the use, 
modification, disposal or return of a medical device. This could be added in the 
process of nonconforming product [78]. 
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Figure 30 - Measurement, analysis and improvement requirements 
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7 USA regulatory process for medical devices 
In the following chapter it is is introduced the regulatory framework for the 
product OneCare Sensing regarding the measures necessary to market the 
product in the US. Since one of the objectives of ISA-Intellicare is to market the 
product in this country it is essential to understand the legal requirements to 
accomplish this. 
7.1 The Food and Drugs Administration 
The Food and Drugs Administration (FDA) is a scientific, regulatory and 
public health agency of the United States Federal Government based in 
Washington DC. It is responsible for protecting public health assuring the safety 
and performance of drugs for animal or human consumption, biological 
products, medical devices, foods, cosmetics and product that emit radiation. In 
2014, it had a $4.4 billion budget with a staff of approximately 15000 employees 
comprising a lot of different areas (lawyers, chemists, physicians, 
microbiologists, etc) [79]. 
The Federal Food, Drug, and Cosmetic Act (FD&C) was passed by Congress 
in 1938 and its following amendments gave authority to the FDA to regulate: 
 Foods 
 Human Prescription and Non-prescription Drugs 
 Vaccines, Blood Products and Other Biologics 
 Medical Devices 
 Electronic Products 
 Cosmetics 
 Veterinary Products 
 Tobacco Products 
This law was passed after the elixir sulfanilamide mass poisoning in 1937 in 
the United States. This disaster caused the death of more than 100 people 
because the elixir contained a component that is lethal to humans. Therefore a 
more strict regulation was needed to control the entering of new drugs in the 
market assuring that they were safe and effective for the users. Others cases 
arisen during history making amendments not only pertinent but essential to 
public health [79]. 
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Figure 31 - FDA logo [80] 
7.2 Process overview 
In figure 32 is depicted the most pertinent USA regulatory process regarding 
the product OneCare Sensing. Other regulatory pathways could be followed for 
different products so these steps cannot be used generally for every type of 
medical devices.  
 
Figure 32 - Steps in FDA's Compliance Process 
7.3 Determine if the product is a medical device 
In section 201(h) of the FD&C [81] a medical device is "an instrument, 
apparatus, implement, machine, contrivance, implant, in vitro reagent, or other 
similar or related article, including a component part, or accessory which is: 
 recognized in the official National Formulary, or the United States 
Pharmacopoeia, or any supplement to them, 
 intended for use in the diagnosis of disease or other conditions, or in 
the cure, mitigation, treatment, or prevention of disease, in man or 
other animals, or 
 intended to affect the structure or any function of the body of man or 
other animals, and which does not achieve its primary intended 
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purposes through chemical action within or on the body of man or 
other animals and which is not dependent upon being metabolized for 
the achievement of any of its primary intended purposes." 
This definition is so vast that it tends to be obvious consider OneCare 
Sensing a medical device but it is essential to be sure. To do this is important to 
read the “ Mobile Medical Applications: Guidance for Industry and Food and 
Drug Administration Staff”  issued on September 25, 2013 [82]. In this 
document our product is a mobile medical app since it falls under the definition 
of a medical device and it is intended to be used as an accessory for regulated 
medical devices. In chapter “V-Regulatory approach for mobile apps, section A-
Mobile medical apps: Subset of mobile apps that are the focus of FDA’ s 
regulatory oversight”, the product falls under the “ Mobile apps that become a 
regulated medical device (software) by performing patient-specific analysis and 
providing patient-specific diagnosis, or treatment recommendations. These types 
of mobile medical apps are similar to or perform the same function as those 
types of software devices that have been previously cleared or approved” . After 
this careful reading and analysis of appendix C-Examples of mobile medical 
apps of the document; OneCare Sensing is considered a mobile medical app that 
falls under FDA regulatory oversight. 
7.4 Device classification 
Device classification is made based upon the level of control necessary to 
assure the safety and efficacy of the device. The three risk classes that exist are: 
 Class I –  General Controls 
o With and without Exemptions 
 Class II –  Special controls in addition to general controls 
o With and without Exemptions 
 Class III –  Premarket Approval in addition to general controls 
The classification of the device depends on three factors: intended use, the 
indications for use and the risks involved. The indications for use are a specific 
part of the intended use which is indicated in the labeling or involved during 
the sale of the product. 
There are two ways of finding a device classification through the FDA 
website: searching in the classification database or by search in the device panel 
(medical specialty). The latest was used and the following information for 
OneCare Sensing was found: 
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Regulatory Number: 21CFR870.2910 
Regulation Name: Radiofrequency physiological signal transmitter and 
receiver 
Regulatory Class: Class II (two) 
The regulatory number involves the regulation name of the device by 
referring to the Code of Federal Regulations Title 21, Part 870 –  
Cardiovascular devices, subpart C –  Cardiovascular Monitoring Devices, Sec. 
870.2910 Radiofrequency physiological signal transmitter and receiver. This text 
was revised in April 1st, 2013. 
With this information it is necessary to access if our device is exempt or not. 
By reviewing the list of medical devices exempt provided by the FDA [83] it is 
concluded that devices with the regulatory number of OneCare Sensing are not 
exempt. 
7.5 Prepare and file 510(k) submission 
When someone wants to market a Class II medical device intended for 
human use must submit a 510(k) to the FDA unless it is exempt. There is not a 
template for this form but in the 21 CFR 807 subpart E, the requirements for 
this type of submission [84] are described. Before the marketing of the device is 
necessary to receive a letter from the FDA which finds the device substantially 
equivalent (SE) and states that the device can be marketed in the USA. 
The objective of this type of submission is to show that the device to be 
marketed is at least as safe and effective to devices already marketed that where 
not subjected to PMA. Submitters must make a comparison between their 
device and other similar medical devices to support that they are substantially 
equivalent (SE). These types of devices are commonly known as the 
“ predicate” . When the device is considered substantially equivalent by the 
FDA it can be marketed in the US. This consideration usually is made within 
90 days based on the information provided in the 510(k). It is important to 
consider that the FDA does not perform 510(k) pre-clearance inspections; this 
means that the manufacturer should be prepared for an inspection regarding the 
compliance with the FDA quality system regulation (21CFR820) as from the 
device is cleared. The price for 510(k) Premarket notification is $2585 for 2014 
since ISA-Intellicare is considered a Small Business by the FDA (has less than 
US$100,000,000 in sales worldwide). 
A device is considered substantially equivalent if: 
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 It has the same intended use as the predicate and the same 
technological characteristics; 
Or 
 It has the same intended use as the predicate and despite does not 
having the same technological characteristics the device does not raise 
new questions related to safety and performance and is at least as safe 
and effective as the legally marketed device. 
Being substantially equivalent does not mean that the devices must be 
exactly identical but they must share a lot of characteristics related to safety 
and performance. 
To search predicate devices for OneCare Sensing was used the FDA 510(k) 
database that contains all devices cleared under the 510(k) process. The 
following four devices where found that could be used as predicate: 
Table 7 - Predicate devices 
Device 510(k) 
Number 
K051470 K132803 K130676 K122458 
Trade/Device 
Name 
Remote Care 
Management 
System 
Medapps 2.0 
Remote Patient 
Monitoring 
System, 
Healthpal, 
Healthcom, 
Mobile Link 
Ambio Remote 
Health Monitoring 
System 
Verizon Wireless 
Converged Health 
Management 
System 
Regulation 
Number 
21 CFR 
870.2910 
21 CFR 870.2910 21 CFR 870.2910 21 CFR 870.2910 
Regulation 
Name 
Physiological 
Signal 
Transmitters 
and Receivers 
Medapps 
Remote Patient 
Monitoring 
System 
Transmitters and 
Receivers, 
Physiological 
Signal, 
Radiofrequency 
Radiofrequency 
Physiological 
Signal Transmitter 
And Receiver 
Regulatory 
Class 
Class II (two) Class II (two) Class II (two) Class II (two) 
Product Code DRG DRG, NBW DRG DRG 
Dated June 1,2005 November 12, 
2013 
May 13, 2013 April 6, 2013 
A more intensive comparison between these systems and OneCare Sensing 
must be made in order to proceed with the 510(k) submission but doing this is 
outside the scope of this project.  
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7.6 Compliance with FDA QSR – 21 CFR Part 820 
A quality system that helps manufacturers to achieve the applicable 
requirements and specifications to their products must be implemented and 
maintained. The FDA Quality system regulation (QSR) according with the 
Code of Federal Regulations (CFR) part 820 also known as current good 
manufacturing practices (CGMP’ s) prescribes the framework for a quality 
system applicable to medical devices - mandatory for manufacturers that 
market this type of products. 
Because this quality system was created before ISO 13485 the FDA does not 
recognize it. Also the FDA does not provide quality system compliance 
certificate. They only conduct random inspections to determine compliance with 
21 CFR Part 820. Usually these inspections are very strict and it is necessary 
for a company to do periodic internal audits to assure that they are at all-time 
compliant. 
Despite ISO 13485 is a different quality system from 21 CFR Part 820 they 
share about 80% of the same requirements [85]. The contents of the FDA 
quality system is presented below, 
FDA 21 CFR 820 
 Subpart A –  General Provision 
o 820.1 Scope 
o 820.3 Definitions 
o 820.5 Quality System 
 Subpart B –  Quality System Requirements 
o 820.20 Management Responsibility 
o 820.22 Quality Audit 
o 820.25 Personnel requirements 
 Subpart C –  Design Control 
o 820.30 Design Controls 
 Subpart D –  Document Control 
o 820.40 Document Controls 
o Subpart E –  Purchasing Controls 
o 820.50 Purchasing Controls 
 Subpart F –  Identification and Traceability 
o 820.60 Identification 
o 820.65 Traceability 
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 Subpart G –  Production and Process Controls 
o 820.70 Production and process controls 
o 820.72 Inspection, measuring and test equipment 
o 820.75 Process Validation 
 Subpart H –  Acceptance Activities 
o 820.80 Receiving, in-process and finished device acceptance 
o 820.86 Acceptance status 
 Subpart I –  Nonconforming product 
o 820.90 Nonconforming product 
 Subpart J –  Corrective and Preventive Action 
o 820.100 Corrective and Preventive Action 
 Subpart K –  Labeling and Package Control 
o 820.120 Device Labeling 
o 820.130 Device Packaging 
 Subpart L –  Handling, Storage, Distribution and Installation 
o 820.140 Handling 
o 820.150 Storage 
o 820.160 Distribution 
o 820.170 Installation 
 Subpart M –  Records 
o 820.180 General Requirements 
o 820.181 Device Master Records 
o 820.184 Device History Records 
o 820.186 Quality System Records 
o 820.198 Complaint Files 
 Subpart N –  Servicing 
o 820.200 Servicing 
 Subpart O –  Statistical Techniques 
o 820.250 Statistical Techniques 
7.7 Appoint US agent 
If the company does not have local presence in the US market it is necessary 
to appoint a US agent as the in-country representative. This agent must either 
be an US resident or maintain a place of business in the US [86]. 
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The responsibilities of this agent are to assist communication between the 
company and the FDA and assist the company and the FDA in setting up the 
random inspections for the foreign establishment. The agent does not have any 
responsibility related to the Medical Device Regulation or the submission of the 
510(k) [86]. 
7.8 Register with the FDA 
Companies that produce or distribute medical devices in the United States 
need to register annually with the FDA. This process is known as establishment 
registration [85]. 
The costs of the registration are depicted in the table below: 
Table 8- Device registration costs with the FDA [87] 
Year 2013 2014 2015 2016 2017 
Fee $2575 $3313 $3750 $3872 $3872 
 
Not only a fee must be paid but it is also required by the FDA to provide a 
list with all the devices made, the activities performed on the devices and the 
premarket notification submission number. This is an electronic registration 
available in the FDA website [79]. 
7.9 Conclusion 
In order to market OneCare Sensing in the USA it is necessary to follow the 
steps referred above. After ISA is ISO 13485:2003 certified it is recommended to 
create a quality plan for implementing 21 CFR Part 820. One great important 
part of this plan is a gap analysis that assesses where the company is and where 
it wants to be regarding the quality system. After this analysis a set of goals 
need to be established and followed to a successful implementation. 
Usually this process takes 8 to 12 months depending on the company type, 
size and resources [85] but since the company is ISO 9001:2008 certified and will 
be ISO 13485:2003 certified in the near future it could only take a couple of 
months. The initial projected costs to market the product in this country will be 
$5898 in 2014. 
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8 Brazil regulatory process for medical devices 
In the following chapter it is introduced the regulatory framework for the 
product OneCare Sensing regarding the measures necessary to market the 
product in Brazil. Since one of the objectives of ISA is to market the product in 
this country it is essential to understand the legal requirements to accomplish 
this.  
8.1 Agência Nacional de Vigilância Sanitária 
According to information provided by the Agência Nacional de Vigilância 
Sanitária (ANVISA) they are a “governmental regulatory agency characterized 
by its administrative Independence, financial autonomy, and the stability of its 
directors.” [88] based in Brazil’s capital Brasília. It is similar to the FDA in the 
United States and responsible for the regulation and approval of various 
products related with the health of Brazilians. The agency was created by Law 
9782 enacted in the 26th January 1999. 
 
Figure 33 - ANVISA logo [89] 
Regarding health related services the agency is responsible for surveillance 
related to risk monitoring improving quality of health services. It coordinates 
actions nationwide carried out by states, municipalities and the Federal district. 
ANVISA is also responsible for formulate and enforce rules regarding health 
provision in hospitals, clinics and health posts [90]. 
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8.2 Process Overview 
In figure 34 is depicted the general regulatory process regarding medical 
devices in Brazil. The specific regulatory pathway for the product OneCare 
Sensing will be presented during this chapter. 
 
 
Figure 34 – Regulatory process for MD in Brazil adapted from [91] 
8.3 Regularization of the company according ANVISA 
This regulatory step starts with obtaining two permits: 
 Autorização de Funcionamento da Empresa (AFE); 
 Licença de Funcionamento local (LF). 
And compliance with the Brazilian Good Manufacturing practices (BGMP). 
Without these two permits it is impossible to market a medical device in Brazil. 
AFE 
This is issued by ANVISA regarding a submission provided by a company 
present in Brazilian territory based in the Normative Instruction no 01 from 30th 
September 1994 [92]. This means that a foreign company that wants to market 
their products in Brazil needs to have a subsidiary office in this country or a 
commercial deal with a company in Brazilian territory to assume legal liability 
to import their products. 
LF 
This one is issued by the local, federal or municipal, Vigilâ ncia Sanitá ria 
Local (VISA) depending in where the company is based in Brazil. These VISAs 
work together with ANVISA to promote the safety and security of the 
population. This license approves the physical installations of the company and 
their working staff [91]. 
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Brazilian Good Manufacturing practices 
A company that wants to manufacture, import or market medical devices in 
Brazil needs to comply with the BGMP established in RDC no 59 from 27th July 
2000 [93]. This is very similar to the requirements established by FDA QSR – 
21 CFR Part 820. After the compliance is assured a certificate, Certificado de 
Boas Práticas de Fabricação e Controle (CBPFC) is issued by ANVISA. 
Site inspections are performed every two years by ANVISA to guarantee 
that the company is following the requirements. In the alternating year 
manufacturers must make an internal audit. There are exemptions to implement 
by quality system but the product OneCare Sensing is not one of them - in the 
following sections this issue will be addressed. 
8.4 Sanitary equipment classification 
This classification must be made according criteria adopted by ANVISA. 
The type of classification of the device will determine the type of petition that 
must be made to the agency. 
Equipment classification 
Medical devices are classified in four classes depending on the risk that it has 
to the patient: 
 Class I –  Low risk; 
 Class II –  Medium risk; 
 Class III –  High risk; 
 Class IV –  Very high risk. 
This risk classification is made by analyzing a set of 18 rules presented in the 
Annex II of RDC no185/01 [94]. These rules are almost equal to the rules 
presented in the European directive 93/42/EEC so in a primordial analysis it is 
safe to assume that OneCare Sensing is a Class II device. 
Economic Information Report 
This report includes pricing comparisons from different markets, patient/user 
information, marketing materials and other materials. It is only applicable to 
some medical devices presented in ANVISA resolution no3385 from 13th October 
2006 [95]. The type of medical product that is OneCare Sensing, is not present 
in this resolution so the economic information report is not applicable. 
INMETRO Certification 
Some electronic medical devices need to obtain INMETRO certification in 
accordance to RDC no. 32 from 29th May 2011 as part of the Brazilian 
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registration process. The products that need this certification are presented in 
IN no. 08 from 29th May 2007 [96]. Again this is not applicable to OneCare 
Sensing since it is a medical software and it is not presented in the IN referred 
above. 
8.5 Petition identification 
There are two types of petitions to register a medical device in Brazil, 
registro or cadastro. Cadastro is a simplified registration procedure for most 
Class I and II devices presented in RDC no. 24/09 in which the company does 
not need the implementation of the BGMP. Registro is a more complex 
procedure for some Class I and II devices and all from Class III and IV in which 
is necessary the implementation of BGMP. According to the technical note no. 
04/2012 [97] issued by ANVISA for a medical software similar to OneCare 
Sensing is necessary a registro. 
According to the registro the following documents need to be presented by a 
manufacturer for a class II medical device: 
 Equipment technical sheet; 
 Technical file; 
 Brazil Good Manufacturing Practices Certificate; 
 Authorization from Brazilian registration holder; 
 Free sales certificate. 
The equipment technical sheet is presented in Annex II of IN 13/2009 [98]. 
The technical file requirements is similar to the one used by the FDA and 
should be prepared according to RDC 185/01 Annex III Part A/B/C and 
provided in Portuguese. Usually companies that already have prepared a 
technical file for CE marking or FDA 510(k) clearance can use the same 
information. A Brazil Good Manufacturing Practices Certificate is also needed 
to assure that the company complies with the quality system requirements.  An 
Authorization from a Brazilian registration holder is necessary for imported 
equipment proving that it can import, distribute and sell products in the 
country. A free sales certificate is also required to prove that the product is 
approved for sale in your home market or a proof of marketing approval in two 
other countries. 
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8.6 Petition submission 
After all the previous steps it is mandatory to submit an electronic petition 
of the registro to ANVISA. To accomplish this, first it is necessary for the 
company to performe its registration with the electronic system of the agency. 
Then one must access ANVISA website and fill the required information. There 
are costs associated with this process that are presented in Annex I, Item 07 
from RDC no. 222, 28th December 2006 [99]. These taxes depend on the nature 
of the petition (registro or cadastro), if it is a simple product or a family of 
products, the size of the product (small, medium or large) and the size of the 
company (micro, small, medium or large). 
8.7 Petition protocol 
In the end of the process the petition needs to be physically filled in 
ANVISA. This is made in the Unidade de Atendimento e Protocolo (UNIAP) in 
the agency headquarters in Brasilia. The petition needs to be signed by the legal 
and technical company representatives. In all documents related to the product 
(instructions for use, labeling, etc) both signatures are needed [91]. 
8.8 Conclusion 
In order to market OneCare Sensing in Brazil it is necessary to follow the 
steps referred above. After marketing of the product is approved in Europe and 
USA it will be fairly easy to fulfill the requirements needed in Brazil. This 
happens because the regulatory process in Brazil shares a lot of characteristics 
with the markets mentioned above despite this the process is usually more slow 
and complex. According to EMERGO GROUP, a regulatory medical devices 
consultant, the approval for marketing a class II product in Brazil could take 
more than 36 months because of the time needed to get the approval for the 
quality system certification [100]. 
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9 Conclusion 
Medical devices are only useful if they are safe and effective. It was showed 
that OneCare Sensing does not provide excessive risks for the users (Annex 4: 
Risk analysis) and its effectiveness is proven by the technology used (Annex 7: 
Evaluation fo clinical data). For the risk analysis the standard ISO 14971:2007 – 
Application of risk management to medical devices was analyzed and 
implemented. Clinical evaluation was compiled using guides from the European 
Commission. The ability to generate alarms and aggretate data from various 
types of sensors to be automatically accessed by the user or clinician are the 
main advantages of this product. 
Remote patient monitoring technology presents a lot of advantages such as 
decrease costs associated with monitoring of chronic diseases, reducing hospital 
stays, deal with reduced medical staff and decrease human errors but there are 
still some barriers to overcome such as difficult acceptance by health care 
organizations and lack of awareness and education. 
According to the MDD OneCare Sensing is a class IIa device with medium 
risk to the user. This implies the involvement of a notified body that will audit 
the technical documentation and quality management system in order to obtain 
CE marking. Following the device panel from the FDA it was showed that the 
product is a class II device without a 510(k) exemption. FDA will perform 
surprise inspections to access compliance with legal requirements related to the 
device. ANVISA RDC no 185/01 indicates that the medical software is a class II 
device and that the implementation of a specific quality management system is 
needed. Similarly to the FDA they also performs inspections on site. 
Regarding Europe the pathway for the implementation of ISO 13485:2003 
was achieved and the technical documentation to comply with the essential 
requirements of the directive was compiled. 
In conclusion the objectives of the work were completed. The legal 
requirements for Europe, USA and Brazil were collected, analyzed and some 
implemented in ISA following the Medical Devices Directive. 
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9.1 Future work 
The purpose of this section is to provide future work suggestions in order to 
fulfill the company objectives regarding the marketing of the product in 
different markets. 
An internal audit of ISA-Intellicare regarding ISO 9001:2008 and ISO 
13485:2003 should be performed in order to be sure that these quality systems 
are correctly implemented and being followed. After this it is recommended to 
have a contact with a notified body in order to obtain a CE certificate for the 
medical device and an ISO 13485:2003 certificate. After this the declaration of 
conformity must be completed and the CE mark can be affixed by the 
manufacturer to the product allowing its marketing in Europe. Maintain and 
continuous improve the quality management system is a must Then, it is 
recommended to implement the quality management systems and generate the 
documentation required to market the product in Brazil and USA. This thesis is 
a good guide to fulfill this objective. 
In a medical devices industry survey from 2013 [1] it was showed that the 
growth potential in the next five years for the Asia and South American market 
will be huge. Japan is still the country that spends more in healthcare but soon 
China will become more competitive. Other countries in southeast Asia are also 
gaining more attention. In the same survey it was asked manufacturers in which 
of emerging markets they where planning to introduce a medical device for the 
first time. The interest in BRIC and Mexico markets is increasing since the 
regulatory systems are becoming more efficient. Brazil was the main answer and 
India came in second for small manufacturers and China for midsized and large 
companies suggesting a simpler and cost effective pathway in India. It is 
important to consider that China, US and Brazil are markets that show a lot of 
regulatory challenges. 
Regarding the previous information it could also benefit ISA-Intellicare to 
understand the regulatory requirements for some Asian countries in a near 
future. 
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9.2 Summary 
Although this was a very theoretical and research work it was essential to 
understand how a company can place a medical device in the market without 
safety and performance issues and following all the mandatory legal 
requirements. Also not having any background in the subject helped me to 
develop more skills such as pro activity, independency and better task 
management. Because the internship was in a company it showed me how a 
management system works and some core business aspects of the industry. 
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